C
PMCB icon

Covestor’s PharmaCyte Biotech PMCB Stock Holding History

Covestor’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
275
– – ﹤0.01% 2764
2026
Q1 		$0 Hold
275
– – ﹤0.01% 2665
2025
Q4 		$0 Hold
275
– – ﹤0.01% 2636
2025
Q3 		$0 Hold
275
– – ﹤0.01% 2652
2025
Q2 		$0 Hold
275
– – ﹤0.01% 2631
2025
Q1 		$0 Hold
275
– – ﹤0.01% 2611
2024
Q4 		$0 Buy
275
+49
+22% +$85 ﹤0.01% 2620
2024
Q3 		$0 Hold
226
– – ﹤0.01% 2630
2024
Q2 		$0 Hold
226
– – ﹤0.01% 2632
2024
Q1 		$1K Hold
226
– – ﹤0.01% 2076
2023
Q4 		$0 Buy
226
+37
+20% +$80 ﹤0.01% 2580
2023
Q3 		$0 Hold
189
– – ﹤0.01% 2570
2023
Q2 		$1K Buy
+189
New +$567 ﹤0.01% 2003

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Covestor's PMCB Position: Q2 2026 in Review

Covestor held its PharmaCyte Biotech (PMCB) position steady in Q2 2026 at 275 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2764.

Covestor first reported a position in PMCB in Q2 2023 and has held it in 13 quarters since. The position peaked at $1K in Q1 2024. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Covestor held 275 shares of PharmaCyte Biotech worth $0 as of Q2 2026.
  • Covestor left its PharmaCyte Biotech share count unchanged in Q2 2026.
  • PharmaCyte Biotech made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2764 holding.
  • Covestor first reported a position in PharmaCyte Biotech in Q2 2023 and has held it in 13 quarters since.
  • Covestor's PharmaCyte Biotech position peaked at $1K in Q1 2024.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.